QUOTE AND NEWS
SeekingAlpha  Aug 6  Comment 
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2014 Results Earnings Conference Call August 5, 2014, 05:00 PM ET Executives Charlie Robb – CFO Joseph Belanoff – CEO and President Steven Lo – VP and Chief Commercial...
DailyFinance  Jun 20  Comment 
CHICAGO, IL -- (Marketwired) -- 06/20/14 -- In the news release, "New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we...
SeekingAlpha  Jun 3  Comment 
By Markus Aarnio: Corcept Therapeutics (CORT) is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. (click to enlarge) Insider buying...
SeekingAlpha  May 8  Comment 
Corcept Therapeutics Inc. (CORT) Q1 2014 Earnings Conference Call May 7, 2014 4:30 PM ET Executives Charlie Robb – CFO Joseph Belanoff – CEO and President Steven Lo – VP and Chief Commercial Officer Analysts Boris...
StreetInsider.com  May 7  Comment 
Corcept Therapeutics, Inc. (Nasdaq: CORT) 47.9% LOWER; reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.41 million versus the consensus estimate of $5.01 million. Quantum Fuel...
TheStreet.com  May 7  Comment 
NEW YORK (TheStreet) -- Corcept Therapeutics  plummeted Wednesday after the company stopped a late-stage trial of its depression treatment drug Mifepristone after analysis determined it was unlikely to succeed. Data analysis from the first 226...
FierceBiotech  May 7  Comment 
Menlo Park, CA's Corcept watched its shares roughly halve Wednesday morning after it pulled the plug on a late-stage trial of an investigational depression treatment.
MarketWatch  May 7  Comment 
Corcept Therapeutics shares lost half their value in premarket trade Wednesday, after the company said it has halted a trial of a psychotic depression drug because it was unlikely to meet its primary endpoint. The announcement came as Corcept...
SeekingAlpha  Apr 16  Comment 
By Bay Area Biotech Investor: Corcept Therapeutics (CORT) is a $368M (as of 4/14/2014) pharmaceutical company located in Menlo Park, CA, with 44 employees. Doctors Joseph Belanoff and Alan Schatzberg co-founded Corcept in 1998. Dr. Belanoff...
StreetInsider.com  Apr 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Corcept+Therapeutics+%28CORT%29+Enters+Manf.+Agreement+with+AAIPharma/9374322.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki